Proximal Ventures raises debut fund to back startups bringing AI to drug

Sahir Raoof, a former principal at SignalFire and healthcare executive, raised $27.5 million for debut solo fund Proximal Ventures to back early startups bringing artificial intelligence to drug development. In TechCrunch's report, the new fund targets software tools and automated services across pharmaceutical research, compound synthesis, and clinical trial data analysis.

This report examines Proximal Ventures' fund strategy, portfolio check sizes, early investments, limited partner syndicate, and founder Sahir Raoof's operational thesis. It is written for life sciences founders, healthcare software engineers, biotech operators, and venture investors tracking emerging solo fund managers in computational medicine.

01The deal behind Proximal Ventures

Raoof secured $27.5 million for his inaugural solo vehicle during a severe contraction across venture fundraising markets. While established firms continue drawing capital, first-time fund managers face one of the steepest fundraising climates in years. Raoof navigated that environment by focusing Proximal Ventures on high-conviction early software investments in life sciences.

Proximal focuses on pre-seed and seed-stage startups, writing initial checks between $500,000 and $1.5 million. The firm has already completed investments in six startups across the computational biology landscape. That check range provides technical founders with operational runway to build initial products before raising larger institutional rounds.

Among the fund's initial six investments is ChronicleBio, a startup co-founded by former OpenAI executive Fidji Simo. ChronicleBio deploys artificial intelligence systems to analyze biological and medical data to understand chronic diseases and identify potential treatments. Backing technical founders at that intersection represents the core focus of Proximal's initial capital.

02Why Proximal Ventures raised

The thesis driving Proximal Ventures stems from historical spending habits across the global pharmaceutical sector. Drug manufacturers have long outsourced labor-intensive stages of development to specialized service providers rather than purchasing software products. Those outsourced services include synthesizing thousands of molecular compounds, designing commercial manufacturing, and analyzing complex clinical trial data.

“For a long time, the assumption was that pharma is not a great buyer of software, but a really good buyer of services,” Raoof told TechCrunch. That historical precedent created entrenched relationships between pharmaceutical corporations and outside vendors. Raoof identified that these recurring service contracts represent accessible entry points for software automation platforms.

Raoof believes artificial intelligence can automate that outsourced work, allowing startups to capture billions of dollars in pharmaceutical spending. Startups leveraging machine learning can deliver those specialized services at lower costs and in less time. Raoof noted that service sectors like law and finance have already demonstrated high-value AI adoption.

03What the Proximal Ventures money

Proximal directs its $27.5 million pool to solve commercial friction points that early life sciences founders encounter. Founders building biological software tools often struggle to convert technological demonstrations into sustained enterprise revenue with pharmaceutical buyers. Raoof structured the vehicle to provide both seed capital and commercial guidance to overcome procurement barriers.

“If you’re building a company that’s selling into the life sciences, one of the hardest things to do is starting that initial commercial flywheel,” Raoof said. Proximal addresses this problem by guiding portfolio companies through early enterprise sales cycles, contract structures, and pilot deployments. Check sizes of $500,000 to $1.5 million fund technical validation without heavy wet-lab operations.

04Competitive context for Proximal Ventures

Raoof spent two years as an investment principal at SignalFire before launching Proximal Ventures, focusing on healthcare and software opportunities. Earlier in his career, he led business development at Iterative Health, an artificial intelligence company developing software for clinical trial recruitment. Those roles gave Raoof direct visibility into how healthcare enterprises adopt novel software.

Prior to Iterative Health, Raoof oversaw strategic partnerships at Flatiron Health, an oncology data company that Swiss pharmaceutical corporation Roche acquired for $1.9 billion in 2018. That combination of venture investing and enterprise partnership negotiation gave limited partners confidence in his ability to identify defensible startups and help founders close enterprise customers.

Proximal's limited partner base reflects a syndicate of prominent venture capital firms and healthcare executives. Institutional backers include SignalFire, Kleiner Perkins, and Bertelsmann Healthcare Investments. Individual limited partners include Dimension Capital co-founders Nan Li and Zavain Dar, providing Proximal with a network of co-investors across early-stage technology and biotechnology sectors.

05Open questions on Proximal Ventures

A key question facing any solo venture fund is whether an independent investor can compete against multi-partner institutional firms with massive capital bases. Amy Abernethy, co-founder of Highlander Health and former principal deputy commissioner of the FDA, joined Proximal's fund as an investor. Abernethy originally met Raoof at Flatiron Health, where she served as chief medical officer.

Abernethy told TechCrunch that Raoof's ability to build relationships and spot industry bottlenecks made a lasting impression during their time working together. She expressed conviction that his operational abilities and market understanding will make him a successful venture investor. Abernethy noted that these qualities have enabled Proximal to invest alongside larger, better-known funds.